Sponsored by:

Business in the Burbs

Movers, shakers and newsmakers

Loss narrows at EpiCept in 2Q


EpiCept Corp., a biotech company based in Tarrytown, reported a net loss of $7.1 million, or 6 cents a share, during the second quarter, compared to a net loss of $7.8 million, or 15 cents a share, a year earlier. Revenues of $91,000 rose from $42,000 a year earlier.

“During the second quarter we continued to advance our important product candidates both commercially and in the clinic,” Chief Executive Officer Jack Talley said.

One of the company’s products is Ceplene, which was approved in the European Union for treatment of patients with Acute Myeloid Leukemia.

This entry was posted on Thursday, August 6th, 2009 at 3:27 pm by Jay Loomis. You can follow any responses to this entry through the RSS 2.0 feed.
Category: Earnings



About this blog
Business in the Burbs is our online news blog about businesses based or operating in the Lower Hudson Valley. Visitors here will also find items of interest to consumers in the region. Most contributions are from business reporters and editors covering Westchester, Rockland and Putnam counties.


Get blog updates via email:

About the Authors


Other recent entries


Monthly Archives